Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
991 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02586987 | A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours | completed | Phase 1 | 58 | AstraZenecaINDUSTRY | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02511795 | AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | completed | Phase 1 | 128 | AstraZenecaINDUSTRY | 2 | Nov 7, 2019 |
| NCT03137264 | Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients(RADIANCE) | completed | — | 44 | AstraZenecaINDUSTRY | 2 | Nov 7, 2019 | clinicaltrials |
| NCT03101839 | Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours | completed | Phase 1 | 28 | AstraZenecaINDUSTRY | 2 | Oct 4, 2019 | clinicaltrials |
| NCT00295620 | Secondary Adjuvant Long Term Study With Arimidex(SALSA) | completed | Phase 3 | 3,484 | AstraZenecaINDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT02093351 | To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer | completed | Phase 1 | 79 | AstraZenecaINDUSTRY | 5 | Oct 2, 2019 | clinicaltrials |
| NCT01894243 | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment | completed | Phase 1 | 31 | AstraZenecaINDUSTRY | 5 | Sep 13, 2019 | clinicaltrials |
| NCT00274469 | A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer(FIRST) | completed | Phase 2 | 205 | AstraZenecaINDUSTRY | 9 | Sep 6, 2019 | clinicaltrials |
| NCT01843062 | Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer(ASTRA) | terminated | Phase 3 | 233 | AstraZenecaINDUSTRY | 8 | Aug 28, 2019 | clinicaltrials |
| NCT02583477 | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 1 / Phase 2 | 23 | AstraZenecaINDUSTRY | 2 | Aug 14, 2019 | clinicaltrials |
| NCT02430311 | The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. | completed | Phase 1 | 36 | AstraZenecaINDUSTRY | 1 | Jul 31, 2019 | clinicaltrials |
| NCT03736473 | A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Jul 8, 2019 | clinicaltrials |
| NCT02248090 | AZD9496 First Time in Patients Ascending Dose Study | completed | Phase 1 | 45 | AstraZenecaINDUSTRY | 3 | Jun 24, 2019 | clinicaltrials |
| NCT03313557 | AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies | completed | Phase 1 | 48 | AstraZenecaINDUSTRY | 4 | Jun 24, 2019 | clinicaltrials |
| NCT03394144 | Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies | completed | Phase 1 | 11 | AstraZenecaINDUSTRY | 1 | Jun 24, 2019 | clinicaltrials |
| NCT03721289 | Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients(PANORAMRETRO) | completed | — | 463 | AstraZenecaINDUSTRY | 4 | Jun 12, 2019 | clinicaltrials |
| NCT03229122 | Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA(CHARLOTTE) | completed | — | 446 | AstraZenecaINDUSTRY | 1 | Jun 10, 2019 | clinicaltrials |
| NCT02122588 | OVArian Cancer Non-Interventional Study - OVATAR(OVATAR) | completed | — | 503 | AstraZenecaINDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT02640755 | Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase(14C) | completed | Phase 1 | 4 | AstraZenecaINDUSTRY | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02155998 | Non-Interventional Study PREVENT(PREVENT) | completed | — | 200 | AstraZenecaINDUSTRY | 1 | Apr 11, 2019 | clinicaltrials |
| NCT02341456 | Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | completed | Phase 1 | 19 | AstraZenecaINDUSTRY | 3 | Mar 25, 2019 | clinicaltrials |
| NCT03333824 | Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer | completed | Phase 1 | 33 | AstraZenecaINDUSTRY | 1 | Mar 25, 2019 | clinicaltrials |
| NCT00979134 | Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours | terminated | Phase 1 | 95 | AstraZenecaINDUSTRY | 7 | Mar 15, 2019 | clinicaltrials |
| NCT00684385 | An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck | approved for marketing | — | — | AstraZenecaINDUSTRY | 4 | Mar 14, 2019 | clinicaltrials |
| NCT02161770 | Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment | completed | Phase 1 | 30 | AstraZenecaINDUSTRY | 6 | Mar 8, 2019 | clinicaltrials |
| NCT01073865 | Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer | completed | Phase 3 | 222 | AstraZenecaINDUSTRY | 6 | Dec 12, 2018 | clinicaltrials |
| NCT02141347 | Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma | completed | Phase 1 | 65 | AstraZenecaINDUSTRY | 1 | Dec 12, 2018 | clinicaltrials |
| NCT03133234 | Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC | completed | — | 47 | AstraZenecaINDUSTRY | 1 | Nov 20, 2018 | clinicaltrials |
| NCT03519958 | Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong | withdrawn | — | 0 | AstraZenecaINDUSTRY | 0 | Nov 16, 2018 | clinicaltrials |
| NCT03649165 | A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants | completed | Phase 1 | 24 | AstraZenecaINDUSTRY | 1 | Nov 8, 2018 | clinicaltrials |
| NCT00683306 | Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment | approved for marketing | — | — | AstraZenecaINDUSTRY | 19 | Sep 13, 2018 | clinicaltrials |
| NCT02558894 | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 2 | 65 | AstraZenecaINDUSTRY | 6 | Aug 2, 2018 | clinicaltrials |
| NCT00494442 | Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer(ICEBERG 2) | completed | Phase 2 | 58 | AstraZenecaINDUSTRY | 5 | Aug 1, 2018 | clinicaltrials |
| NCT02317016 | Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 4 | Jul 31, 2018 | clinicaltrials |
| NCT02403895 | AZD2014 and Weekly Paclitaxel in Squamous NSCLC | terminated | Phase 2 | 11 | AstraZenecaINDUSTRY | 3 | Jul 3, 2018 | clinicaltrials |
| NCT00890825 | AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients | completed | Phase 2 | 88 | AstraZenecaINDUSTRY | 12 | Jun 20, 2018 | clinicaltrials |
| NCT03063710 | Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan | no longer available | — | — | AstraZenecaINDUSTRY | 1 | May 17, 2018 | clinicaltrials |
| NCT03315091 | Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours | completed | Phase 1 | 31 | AstraZenecaINDUSTRY | 3 | Apr 30, 2018 | clinicaltrials |
| NCT01809210 | Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer(SELECT-3) | completed | Phase 1 | 55 | AstraZenecaINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT00707707 | Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer | completed | Phase 1 | 19 | AstraZenecaINDUSTRY | 4 | Mar 6, 2018 | clinicaltrials |
| NCT03037086 | Asia PDL1 Study Among NSCLC Patients(MEDI-APEX) | completed | — | 658 | AstraZenecaINDUSTRY | 3 | Feb 28, 2018 | clinicaltrials |
| NCT03053297 | Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)(PANORAMA) | terminated | — | 89 | AstraZenecaINDUSTRY | 6 | Feb 8, 2018 | clinicaltrials |
| NCT01813474 | Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies | completed | Phase 1 | 23 | AstraZenecaINDUSTRY | 1 | Jan 16, 2018 | clinicaltrials |
| NCT01425294 | Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment | terminated | — | 231 | AstraZenecaINDUSTRY | 1 | Dec 5, 2017 | clinicaltrials |
| NCT02543476 | SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)(SUPREME-HN) | completed | — | 412 | AstraZenecaINDUSTRY | 7 | Nov 14, 2017 | clinicaltrials |
| NCT03079687 | Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | approved for marketing | — | — | AstraZenecaINDUSTRY | 1 | Oct 25, 2017 | clinicaltrials |
| NCT02406235 | Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer(ENGAGE) | completed | — | 710 | AstraZenecaINDUSTRY | 3 | Sep 19, 2017 | clinicaltrials |
| NCT01851265 | D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 3 | Aug 28, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials